Bioactivity in an aggrecan 32-mer fragment is mediated via toll-like receptor 2

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1240-1249

  Lees, Sophie ^a   Golub, Suzanne B ^a   Last, Karena ^a   Zeng, Weiguang ^a   Jackson, David C ^a   Sutton, Philip ^a   Fosang, Amanda J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

32 MER PEPTIDE; AGGRECAN; AGGRECAN 32 MER FRAGMENT; COLLAGENASE 3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MACROPHAGE ELASTASE; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; STROMELYSIN; SYNTHETIC PEPTIDE; TOLL LIKE RECEPTOR 2; UNCLASSIFIED DRUG; PEPTIDE FRAGMENT;

ALPHALISA; ANALYTIC METHOD; ANIMAL CELL; ARTICLE; BIOLOGICAL ACTIVITY; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL STIMULATION; CONTROLLED STUDY; DOSE RESPONSE; FIBROBLAST; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUCIFERASE ASSAY; MOUSE; NONHUMAN; PERITONEUM MACROPHAGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SYNOVIAL FIBROBLAST; WESTERN BLOTTING; ADOLESCENT; ANIMAL; CELL LINE; CYTOLOGY; DRUG EFFECTS; GENETICS; MALE; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; SYNOVIUM;

ADOLESCENT; AGGRECANS; ANIMALS; BLOTTING, WESTERN; CELL LINE; CHONDROCYTES; FIBROBLASTS; HUMANS; INTERLEUKIN-6; MACROPHAGES, PERITONEAL; MALE; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; MICE; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PEPTIDE FRAGMENTS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTOR 2;

EID: 84928648838     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39063     Document Type: Article

References (54)

1. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, et al. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage. J Clin Invest 1996; 97: 761-8.
2. De Lange-Brokaar BJ, Ioan-Facsinay A, van Osch GJ, Zuurmond AM, Schoones J, Toes RE, et al. Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review. Osteoarthritis Cartilage 2012; 20: 1484-99.
3. Aderem A, Ulevitch RJ., Toll-like receptors in the induction of the innate immune response. Nature 2000; 406: 782-7.
4. Kaisho T, Akira S., Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol 2001; 22: 78-83.
5. Foell D, Wittkowski H, Roth J., Mechanisms of disease: a 'DAMP' view of inflammatory arthritis. Nat Clin Pract Rheumatol 2007; 3: 382-90.
6. Page TH, Midwood KS., Targeting DAMP activation of Toll-like receptors: novel pathways to treat rheumatoid arthritis ? In:, Lemmey A, editor. Rheumatoid arthritis: treatment. Rijeka (Croatia): InTech; 2012. p. 211-32.
7. Scanzello CR, Goldring SR., The role of synovitis in osteoarthritis pathogenesis. Bone 2012; 51: 249-57.
8. Goh FG, Midwood KS., Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology (Oxford) 2012; 51: 7-23.
9. Choe JY, Crain B, Wu SR, Corr M., Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by Toll-like receptor 4 signaling. J Exp Med 2003; 197: 537-42.
10. Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008; 118: 205-16.
11. Kyo F, Futani H, Matsui K, Terada M, Adachi K, Nagata K, et al. Endogenous interleukin-6, but not tumor necrosis factor α, contributes to the development of Toll-like receptor 4/myeloid differentiation factor 88-mediated acute arthritis in mice. Arthritis Rheum 2005; 52: 2530-40.
12. Zhang Q, Hui W, Litherland GJ, Barter MJ, Davidson R, Darrah C, et al. Differential Toll-like receptor-dependent collagenase expression in chondrocytes. Ann Rheum Dis 2008; 67: 1633-41.
13. Su SL, Tsai CD, Lee CH, Salter DM, Lee HS., Expression and regulation of Toll-like receptor 2 by IL-1β and fibronectin fragments in human articular chondrocytes. Osteoarthritis Cartilage 2005; 13: 879-86.
14. Sillat T, Barreto G, Clarijs P, Soininen A, Ainola M, Pajarinen J, et al. Toll-like receptors in human chondrocytes and osteoarthritic cartilage. Acta Orthop 2013; 84: 585-92.
15. Liu-Bryan R, Terkeltaub R., Chondrocyte innate immune myeloid differentiation factor 88-dependent signaling drives procatabolic effects of the endogenous Toll-like receptor 2/Toll-like receptor 4 ligands low molecular weight hyaluronan and high mobility group box chromosomal protein 1 in mice. Arthritis Rheum 2010; 62: 2004-12.
16. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002; 195: 99-111.
17. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, et al. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009; 15: 774-80.
18. Gondokaryono SP, Ushio H, Niyonsaba F, Hara M, Takenaka H, Jayawardana ST, et al. The extra domain A of fibronectin stimulates murine mast cells via Toll-like receptor 4. J Leukoc Biol 2007; 82: 657-65.
19. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005; 115: 2223-33.
20. Bock HC, Michaeli P, Bode C, Schultz W, Kresse H, Herken R, et al. The small proteoglycans decorin and biglycan in human articular cartilage of late-stage osteoarthritis. Osteoarthritis Cartilage 2001; 9: 654-63.
21. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhao JG, et al. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and microRNA-21. Sci Signal 2011; 4: ra75.
22. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009; 457: 102-6.
23. Piccinini AM, Midwood KS., DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010; 2010: 672395.
24. Schelbergen RF, Blom AB, van den Bosch MH, Sloetjes A, Abdollahi-Roodsaz S, Schreurs BW, et al. Alarmins S100A8 and S100A9 elicit a catabolic effect in human osteoarthritic chondrocytes that is dependent on Toll-like receptor 4. Arthritis Rheum 2012; 64: 1477-87.
25. Verzijl N, DeGroot J, Bank RA, Bayliss MT, Bijlsma JW, Lafeber FP, et al. Age-related accumulation of the advanced glycation endproduct pentosidine in human articular cartilage aggrecan: the use of pentosidine levels as a quantitative measure of protein turnover. Matrix Biol 2001; 20: 409-17.
26. Maroudas A, Bayliss MT, Uchitel-Kaushansky N, Schneiderman R, Gilav E., Aggrecan turnover in human articular cartilage: use of aspartic acid racemization as a marker of molecular age. Arch Biochem Biophys 1998; 350: 61-71.
27. Vilim V, Fosang AJ., Proteoglycans isolated from dissociative extracts of differently-aged human articular cartilage: characterization of naturally-occurring hyaluronan-binding fragments of aggrecan. Biochem J 1994; 304: 887-94.
28. Abbaszade I, Liu RQ, Yang F, Rosenfeld SA, Ross OH, Link JR, et al. Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 1999; 274: 23443-50.
29. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis JM, Liu R, et al. Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science 1999; 284: 1664-6.
30. Fosang AJ, Neame PJ, Hardingham TE, Murphy G, Hamilton JA., Cleavage of cartilage proteoglycan between G1 and G2 domains by stromelysins. J Biol Chem 1991; 266: 15579-82.
31. Fosang AJ, Last K, Knauper V, Murphy G, Neame PJ., Degradation of cartilage aggrecan by collagenase-3 (MMP-13). FEBS Lett 1996; 380: 17-20.
32. Embry Flory JJ, Fosang AJ, Knudson W., The accumulation of intracellular ITEGE and DIPEN neoepitopes in bovine articular chondrocytes is mediated by CD44 internalization of hyaluronan. Arthritis Rheum 2006; 54: 443-54.
33. Fosang AJ, Last K, Poon CJ, Plaas AH., Keratan sulphate in the interglobular domain has a microstructure that is distinct from keratan sulphate elsewhere on pig aggrecan. Matrix Biol 2009; 28: 53-61.
34. Rogerson FM, Chung YM, Deutscher ME, Last K, Fosang AJ., Cytokine-induced increases in ADAMTS-4 messenger RNA expression do not lead to increased aggrecanase activity in ADAMTS-5-deficient mice. Arthritis Rheum 2010; 62: 3365-73.
35. Hornung V, Bauernfeind F, Halle A, Samstad EO, Kono H, Rock KL, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008; 9: 847-56.
36. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3:RESEARCH0034.
37. Zeng W, Eriksson E, Chua B, Grollo L, Jackson DC., Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys. Amino Acids 2010; 39: 471-80.
38. Stanton H, Ung L, Fosang AJ., The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases. Biochem J 2002; 364: 181-90.
39. Fosang AJ, Last K, Gardiner P, Jackson DC, Brown L., Development of a cleavage site-specific monoclonal antibody for detecting metalloproteinase-derived aggrecan fragments: detection of fragments in human synovial fluids. Biochem J 1995; 310: 337-43.
40. O'Neill LA., The interleukin-1 receptor/Toll-like receptor superfamily: 10 years of progress. Immunol Rev 2008; 226: 10-8.
41. Leung BP, Xu D, Culshaw S, McInnes IB, Liew FY., A novel therapy of murine collagen-induced arthritis with soluble T1/ST2. J Immunol 2004; 173: 145-50.
42. Liu-Bryan R, Terkeltaub R., The growing array of innate inflammatory ignition switches in osteoarthritis [editorial]. Arthritis Rheum 2012; 64: 2055-8.
43. Goldring MB, Otero M., Inflammation in osteoarthritis. Curr Opin Rheumatol 2011; 23: 471-8.
44. Sellam J, Berenbaum F., The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis. Nat Rev Rheumatol 2010; 6: 625-35.
45. Kim HA, Cho ML, Choi HY, Yoon CS, Jhun JY, Oh HJ, et al. The catabolic pathway mediated by Toll-like receptors in human osteoarthritic chondrocytes. Arthritis Rheum 2006; 54: 2152-63.
46. Nair A, Kanda V, Bush-Joseph C, Verma N, Chubinskaya S, Mikecz K, et al. Synovial fluid from patients with early osteoarthritis modulates fibroblast-like synoviocyte responses to Toll-like receptor 4 and Toll-like receptor 2 ligands via soluble CD14. Arthritis Rheum 2012; 64: 2268-77.
47. Blom A, van Lent P, Abdollahi-Roodsaz S, van der Kraan PM, van den Berg WB,. Toll like receptor-2 activation prevents cartilage damage in osteoarthritis models that display synovial activation [abstract]. Arthritis Rheum 2011; 63 Suppl: S82-3.
48. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. J Biol Chem 2000; 275: 39027-31.
49. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum 2008; 58: 2420-31.
50. Stoop R, van der Kraan PM, Buma P, Hollander AP, Poole AR, van den Berg WB., Denaturation of type II collagen in articular cartilage in experimental murine arthritis: evidence for collagen degradation in both reversible and irreversible cartilage damage. J Pathol 1999; 188: 329-37.
51. Thomas L., Reversible collapse of rabbit ears after intravenous papain, and prevention of recovery by cortisone. J Exp Med 1956; 104: 245-61.
52. Fosang AJ, Last K, Maciewicz RA., Aggrecan is degraded by matrix metalloproteinases in human arthritis: evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest 1996; 98: 2292-9.
53. Flannery CR, Little CB, Caterson B., Molecular cloning and sequence analysis of the aggrecan interglobular domain from porcine, equine, bovine and ovine cartilage: comparison of proteinase-susceptible regions and sites of keratan sulfate substitution. Matrix Biol 1998; 16: 507-11.
54. Brown GM, Huckerby TN, Bayliss MT, Nieduszynski IA., Human aggrecan keratan sulfate undergoes structural changes during adolescent development. J Biol Chem 1998; 273: 26408-14.